Table 3.
Discriminatory capability of biomarker panels
| Affected area | MFI | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomarker candidate | Control vs. cohort | AUC | 95% Confidence interval | Sensit. at 90% specif. | AUC | 95% Confidence interval | Sensit. at 90% specif. | |||||
| CD38 and CD11b | RA | 0.77 | 0.61 | - | 0.94 | 46.82 | 0.77 | 0.61 | - | 0.94 | 44.95 | |
| RA(+) | 0.69 | 0.48 | - | 0.89 | 28.45 | 0.70 | 0.49 | - | 0.90 | 29.12 | ||
| RA(++) | 0.97 | 0.87 | - | 1.00 | 91.98 | 0.94 | 0.83 | - | 1.00 | 83.20 | ||
| CD304 and CD64 | RA | 0.84 | 0.71 | - | 0.98 | 66.16 | 0.79 | 0.63 | - | 0.95 | 65.08 | |
| RA(+) | 0.78 | 0.59 | - | 0.96 | 51.07 | 0.70 | 0.48 | - | 0.92 | 49.88 | ||
| RA(++) | 1.00 | 1.00 | - | 1.00 | 100.00 | 1.00 | 1.00 | - | 1.00 | 100.00 | ||
| CD90 and CD29 | RA | 0.81 | 0.67 | - | 0.96 | 56.42 | 0.83 | 0.68 | - | 0.97 | 55.84 | |
| RA(+) | 0.86 | 0.72 | - | 1.00 | 70.98 | 0.86 | 0.72 | - | 1.00 | 66.31 | ||
| RA(++) | 0.67 | 0.42 | - | 0.92 | 9.24 | 0.75 | 0.49 | - | 1.00 | 35.48 | ||
| HLA-DR and CD90 | RA | 0.87 | 0.74 | - | 0.99 | 65.46 | 0.87 | 0.74 | - | 0.99 | 66.53 | |
| RA(+) | 0.89 | 0.75 | - | 1.00 | 73.92 | 0.90 | 0.77 | - | 1.00 | 75.96 | ||
| RA(++) | 0.83 | 0.61 | - | 1.00 | 53.85 | 0.79 | 0.54 | - | 1.00 | 51.55 | ||
| HLA-DR and CD29 | RA | 0.86 | 0.74 | - | 0.99 | 63.02 | 0.88 | 0.76 | - | 1.00 | 69.08 | |
| RA(+) | 0.88 | 0.75 | - | 1.00 | 69.96 | 0.93 | 0.83 | - | 1.00 | 81.57 | ||
| RA(++) | 0.84 | 0.66 | - | 1.00 | 44.26 | 0.76 | 0.49 | - | 1.00 | 47.12 | ||
| CD29, CD90, and HLA-DR | RA | 0.90 | 0.79 | - | 1.00 | 70.64 | 0.90 | 0.79 | - | 1.00 | 72.25 | |
| RA(+) | 0.91 | 0.79 | - | 1.00 | 78.20 | 0.95 | 0.86 | - | 1.00 | 83.07 | ||
| RA(++) | 0.87 | 0.69 | - | 1.00 | 58.44 | 0.71 | 0.46 | - | 0.97 | 56.13 | ||
Listed panels of potential biomarkers were labeled simultaneously by the respective antibodies on synovial tissue and analyzed with LSC. Data were obtained with ROC analysis. Bold, AUC > 0.85.